{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:54:03Z","timestamp":1794243243150,"version":"4.9.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CRUK A6791"],"award-info":[{"award-number":["CRUK A6791"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1024232"],"award-info":[{"award-number":["APP1024232"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009053","name":"DBT\/Wellcome Trust India Alliance","doi-asserted-by":"publisher","award":["IA\/M\/12\/500755"],"award-info":[{"award-number":["IA\/M\/12\/500755"]}],"id":[{"id":"10.13039\/501100009053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001102","name":"Cancer Council NSW","doi-asserted-by":"publisher","award":["PG16-01"],"award-info":[{"award-number":["PG16-01"]}],"id":[{"id":"10.13039\/501100001102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007311","name":"Deutsche Kinderkrebsstiftung","doi-asserted-by":"publisher","award":["DKS 2007.02\/2012.21\/2016.08\/2019.05"],"award-info":[{"award-number":["DKS 2007.02\/2012.21\/2016.08\/2019.05"]}],"id":[{"id":"10.13039\/501100007311","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ejca.2021.03.034","type":"journal-article","created":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T11:43:57Z","timestamp":1621165437000},"page":"175-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1039-2872","authenticated-orcid":false,"given":"Cornelia","family":"Eckert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3826-2554","authenticated-orcid":false,"given":"Catriona","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony V.","family":"Moorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie AE.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6335-3274","authenticated-orcid":false,"given":"Renate","family":"Kirschner-Schwabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0612-7913","authenticated-orcid":false,"given":"Stefanie","family":"Groeneveld-Krentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6718-3222","authenticated-orcid":false,"given":"Tamas","family":"R\u00e9v\u00e9sz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hoogerbrugge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5756-4470","authenticated-orcid":false,"given":"Jeremy","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenter","family":"Henze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Chen-Santel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andishe","family":"Attarbaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bourquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Sramkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6769-3847","authenticated-orcid":false,"given":"Shekhar","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend","family":"von Stackelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaskar","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejca.2021.03.034_bib1","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1182\/blood-2010-07-294678","article-title":"Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group","volume":"117","author":"Freyer","year":"2011","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.ejca.2021.03.034_bib2","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90","volume":"28","author":"Tallen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.03.034_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.2005.05572.x","article-title":"Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial","volume":"130","author":"Roy","year":"2005","journal-title":"Br J Haematol"},{"issue":"36","key":"10.1016\/j.ejca.2021.03.034_bib4","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1200\/JCO.19.01694","article-title":"Improving stratification for children with late bone marrow B-cell acute lymphoblastic leukemia relapses with refined response classification and integration of genetics","volume":"37","author":"Eckert","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.03.034_bib5","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/S2352-3026(19)30003-1","article-title":"Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial","volume":"6","author":"Parker","year":"2019","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.ejca.2021.03.034_bib6","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1182\/blood.V101.10.3835","article-title":"Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis","volume":"101","author":"Borgmann","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ejca.2021.03.034_bib7","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Children's Oncology G. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.ejca.2021.03.034_bib8","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2015.59","article-title":"Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment","volume":"29","author":"Eckert","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.ejca.2021.03.034_bib9","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood.V78.5.1166.1166","article-title":"Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group","volume":"78","author":"Henze","year":"1991","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.ejca.2021.03.034_bib10","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","article-title":"Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children's Oncology Group Study[corrected]","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.03.034_bib11","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-134774","article-title":"A Phase I study of inotuzumab ozogamicin in pediatric relapsed\/refractory acute lymphoblastic leukemia (ITCC-059 study)","author":"Brivio","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.03.034_bib12","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2021.03.034_bib13","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ejca.2021.03.034_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-018-0117-0","article-title":"Survival after blinatumomab treatment in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"8","author":"Gore","year":"2018","journal-title":"Blood Canc J"},{"issue":"8","key":"10.1016\/j.ejca.2021.03.034_bib15","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2021.03.034_bib16","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41375-020-0770-8","article-title":"Blinatumomab versus historical standard therapy in pediatric patients with relapsed\/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia","volume":"34","author":"Locatelli","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.ejca.2021.03.034_bib17","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"9967","key":"10.1016\/j.ejca.2021.03.034_bib18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"9757","key":"10.1016\/j.ejca.2021.03.034_bib19","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","article-title":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial","volume":"376","author":"Parker","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2021.03.034_bib20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/bjh.15770","article-title":"Aneuploidy in children with relapsed B-cell precursor acute lymphoblastic leukaemia: clinical importance of detecting a hypodiploid origin of relapse","volume":"185","author":"Groeneveld-Krentz","year":"2019","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.ejca.2021.03.034_bib21","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.2011.34.8144","article-title":"Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia","volume":"29","author":"Hof","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2021.03.034_bib22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1182\/blood-2016-03-704973","article-title":"Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia","volume":"128","author":"Irving","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejca.2021.03.034_bib23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/leu.2012.155","article-title":"Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia","volume":"27","author":"Krentz","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.ejca.2021.03.034_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108107","article-title":"Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trial","volume":"9","author":"Masurekar","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.ejca.2021.03.034_bib25","article-title":"Allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation for hematologic malignancies in children: a systematic review and meta-analysis","author":"Shimosato","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.ejca.2021.03.034_bib26","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.bmt.1704241","article-title":"Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group","volume":"32","author":"Krejci","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.ejca.2021.03.034_bib27","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/sj.leu.2402552","article-title":"Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL","volume":"16","author":"Bader","year":"2002","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ejca.2021.03.034_bib28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","article-title":"Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group","volume":"27","author":"Bader","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2021.03.034_bib29","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","article-title":"Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL","volume":"131","author":"Wood","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2021.03.034_bib30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1200\/JCO.2017.74.0449","article-title":"Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia","volume":"36","author":"O'Connor","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.03.034_bib31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-014-0071-7","article-title":"Notch1-induced T cell leukemia can be potentiated by microenvironmental cues in the spleen","volume":"7","author":"Ma","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2021.03.034_bib32","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1016\/j.bbmt.2015.08.023","article-title":"Transplant outcomes for children with T cell acute lymphoblastic leukemia in second remission: a report from the center for international blood and marrow transplant research","volume":"21","author":"Burke","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ejca.2021.03.034_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group","author":"Horton","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.ejca.2021.03.034_bib34","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/bjh.16005","article-title":"Efficacy and safety of a bortezomib and reduced-intensity cytarabine-based protocol, TMC ALLR1, for relapsed childhood ALL in India","volume":"186","author":"Roy","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.ejca.2021.03.034_bib35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/ng.2532","article-title":"The genomic landscape of hypodiploid acute lymphoblastic leukemia","volume":"45","author":"Holmfeldt","year":"2013","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.ejca.2021.03.034_bib36","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ng.3362","article-title":"Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options","volume":"47","author":"Fischer","year":"2015","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.ejca.2021.03.034_bib37","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1158\/0008-5472.CAN-18-0236","article-title":"Bcl-2 is a therapeutic target for hypodiploid B-lineage acute lymphoblastic leukemia","volume":"79","author":"Diaz-Flores","year":"2019","journal-title":"Can Res"},{"issue":"1","key":"10.1016\/j.ejca.2021.03.034_bib38","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3324\/haematol.2018.199364","article-title":"Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia","volume":"105","author":"Demir","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.ejca.2021.03.034_bib39","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3324\/haematol.2018.210104","article-title":"Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation","volume":"104","author":"Mouttet","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.ejca.2021.03.034_bib40","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","article-title":"Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia","volume":"20","author":"Richard-Carpentier","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement_1","key":"10.1016\/j.ejca.2021.03.034_bib41","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-126977","article-title":"Safety and efficacy of venetoclax in combination with navitoclax in adult and pediatric relapsed\/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"134","author":"Lacayo","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ejca.2021.03.034_bib42","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejca.2021.03.034_bib43","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2019000904","article-title":"Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia","volume":"134","author":"Vogiatzi","year":"2019","journal-title":"Blood"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492100201X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492100201X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:31:38Z","timestamp":1777599098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492100201X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":43,"alternative-id":["S095980492100201X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.03.034","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.03.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}